Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR, After >= 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hughes, Timothy P
  • Lipton, Jeffrey H
  • Leber, Brian
  • Spector, Nelson
  • Cervantes, Francisco
  • Pasquini, Ricardo
  • Clementino, Nelma
  • Schwarer, Anthony P
  • Mahon, Francois-Xavier
  • Rea, Delphine
  • Yeung, David T
  • Kamel-Reid, Suzanne
  • Bendit, Israel
  • Reynolds, John
  • Williams, Lisa
  • Szczudlo, Tomasz
  • Branford, Susan

publication date

  • November 18, 2011

published in